Beech Hill Advisors Inc. Has $3.04 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Beech Hill Advisors Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 9.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 19,392 shares of the company’s stock after selling 2,077 shares during the period. Johnson & Johnson makes up approximately 1.5% of Beech Hill Advisors Inc.’s holdings, making the stock its 26th largest position. Beech Hill Advisors Inc.’s holdings in Johnson & Johnson were worth $3,040,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in JNJ. Hibernia Wealth Partners LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at approximately $27,000. FNY Investment Advisers LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at approximately $37,000. Tower View Wealth Management LLC raised its holdings in Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 165 shares in the last quarter. Creative Capital Management Investments LLC raised its holdings in Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after acquiring an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at approximately $48,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 28th. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $180.00 in a report on Friday, December 1st. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $177.31.

View Our Latest Analysis on Johnson & Johnson

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.4 %

NYSE JNJ opened at $156.21 on Wednesday. The firm has a market cap of $376.43 billion, a PE ratio of 11.31, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The stock’s 50 day simple moving average is $159.37 and its 200 day simple moving average is $156.84. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The business’s quarterly revenue was down 9.7% compared to the same quarter last year. During the same period last year, the company earned $2.35 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were given a $1.19 dividend. The ex-dividend date was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.05%. Johnson & Johnson’s payout ratio is 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.